• Je něco špatně v tomto záznamu ?

2018 worldwide survey of health-care providers caring for patients with narcolepsy: WSS narcolepsy task force

L. Rosenthal, MJ. Thorpy, S. Nevsimalova, G. Mayer, F. Han, Y. Dauvilliers

. 2021 ; 82 (-) : 23-28. [pub] 20210315

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025697

BACKGROUND: There are limited data available on regional differences in the diagnosis and management of narcolepsy. In order to better understand worldwide trends in clinical assessment and management of narcolepsy, a survey of health-care providers was conducted by the World Sleep Society Narcolepsy task force. METHODS: A total of 146 surveys that included items on the diagnosis and management of narcolepsy were completed by practitioners representing 37 countries. RESULTS: Most of the participants were from Europe, North America, Oceania, Asia and Latin America. A consistent approach to applying the diagnostic criteria of Narcolepsy was documented with the exception of measurement of CSF hypocretin-1, which has limited availability. While the majority of practitioners (58%) reported not using the test, 1% indicated always evaluating CSF hypocretin-1 levels. There was much variability in the availability of currently recommended medications such as sodium oxybate and pitolisant; modafinil and antidepressants were the most commonly used medications. Amphetamines were unavailable in some countries. CONCLUSION: The results of the study highlight clinical and therapeutic realities confronted by worldwide physicians in the management of narcolepsy. While the diagnostic criteria of narcolepsy rely in part on the quantification of CSF hypocretin-1, few physicians reported having incorporated this test into their routine assessment of the condition. Regional differences in the management of narcolepsy appeared to be related to geographic availability and expense of the therapeutic agents.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025697
003      
CZ-PrNML
005      
20211026133603.0
007      
ta
008      
211013s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.sleep.2021.03.014 $2 doi
035    __
$a (PubMed)33873103
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Rosenthal, Leon $u Sleep Medicine Associates of Texas, Dallas, TX, USA. Electronic address: lrosenthal@sleepmed.com
245    10
$a 2018 worldwide survey of health-care providers caring for patients with narcolepsy: WSS narcolepsy task force / $c L. Rosenthal, MJ. Thorpy, S. Nevsimalova, G. Mayer, F. Han, Y. Dauvilliers
520    9_
$a BACKGROUND: There are limited data available on regional differences in the diagnosis and management of narcolepsy. In order to better understand worldwide trends in clinical assessment and management of narcolepsy, a survey of health-care providers was conducted by the World Sleep Society Narcolepsy task force. METHODS: A total of 146 surveys that included items on the diagnosis and management of narcolepsy were completed by practitioners representing 37 countries. RESULTS: Most of the participants were from Europe, North America, Oceania, Asia and Latin America. A consistent approach to applying the diagnostic criteria of Narcolepsy was documented with the exception of measurement of CSF hypocretin-1, which has limited availability. While the majority of practitioners (58%) reported not using the test, 1% indicated always evaluating CSF hypocretin-1 levels. There was much variability in the availability of currently recommended medications such as sodium oxybate and pitolisant; modafinil and antidepressants were the most commonly used medications. Amphetamines were unavailable in some countries. CONCLUSION: The results of the study highlight clinical and therapeutic realities confronted by worldwide physicians in the management of narcolepsy. While the diagnostic criteria of narcolepsy rely in part on the quantification of CSF hypocretin-1, few physicians reported having incorporated this test into their routine assessment of the condition. Regional differences in the management of narcolepsy appeared to be related to geographic availability and expense of the therapeutic agents.
650    _2
$a lidé $7 D006801
650    12
$a narkolepsie $x diagnóza $x farmakoterapie $7 D009290
650    _2
$a orexiny $7 D000068797
650    _2
$a péče o pacienta $7 D005791
650    _2
$a polysomnografie $7 D017286
651    _2
$a Asie $7 D001208
651    _2
$a Evropa $7 D005060
651    _2
$a Severní Amerika $7 D009656
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Thorpy, Michael J $u Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, NY, USA
700    1_
$a Nevsimalova, Sona $u Department of Neurology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mayer, Geert $u Department of Neurology, Hephata Klinik, Schwalmstadt, Germany; Philipps University, Marburg, Germany
700    1_
$a Han, Fang $u Department of Pulmonary Medicine, Beijing University People's Hospital, Beijing, China
700    1_
$a Dauvilliers, Yves $u National Reference Network for Narcolepsy, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de- Chauliac Hospital, CHU Montpellier, Univ Montpellier, Institute of Neuroscience INM INSERM, Montpellier, France
773    0_
$w MED00006025 $t Sleep medicine $x 1878-5506 $g Roč. 82, č. - (2021), s. 23-28
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33873103 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133609 $b ABA008
999    __
$a ok $b bmc $g 1714648 $s 1146204
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 82 $c - $d 23-28 $e 20210315 $i 1878-5506 $m Sleep medicine $n Sleep Med $x MED00006025
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace